Primary focal segmental glomerulosclerosis

Summary

Primary focal segmental glomerulosclerosis (MONDO:0100324) is a disease and 7 clinical trials. Top therapeutic interventions include basiliximab, rituximab, and bleselumab. A subtype of focal segmental glomerulosclerosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	primary focal segmental glomerulosclerosis
Mondo ID	MONDO:0100324
UMLS	C1709661
MedGen	313617
GARD	0026145
Is cancer (heuristic)	no

Disease family

This is a subtype of focal segmental glomerulosclerosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › glomerular disorder › glomerulosclerosis › focal segmental glomerulosclerosis › primary focal segmental glomerulosclerosis

Related subtypes (1): inherited focal segmental glomerulosclerosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	6
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06466135	PHASE2	RECRUITING	Study of WAL0921 in Patients With Glomerular Kidney Diseases
NCT01573533	PHASE2	COMPLETED	A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
NCT01665391	PHASE2	COMPLETED	A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
NCT02921789	PHASE2	COMPLETED	Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
NCT03422510	PHASE2	COMPLETED	FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
NCT04983888	PHASE2	COMPLETED	Obinutuzumab in Primary FSGS
NCT06315504	Not specified	NOT_YET_RECRUITING	Circulating Factors in Nephrotic Syndrome

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BASILIXIMAB	4	1
RITUXIMAB	4	1
BLESELUMAB	2	1
CXA-10	2	1
FRESOLIMUMAB	2	1